Key result
Oral clonidine (5 microg/kg) decreased middle cerebral artery mean blood flow velocity from 62 to 48 cm/s and attenuated cerebral CO2 vasoreactivity in human volunteers.
Why the study?
Does oral clonidine decrease cerebral blood flow velocity and CO2 vasoreactivity in human volunteers?
Does oral clonidine decrease cerebral blood flow velocity and CO2 vasoreactivity in human volunteers?
Oral clonidine decreases cerebral blood flow velocity and mildly attenuates CO2 vasoreactivity in human volunteers.
Answers are grounded in this paper and cite their sources.
Clonidine may reduce cerebral flow velocity and CO2 reactivity in volunteers; leaves open clinical relevance in neurosurgical patients.
BACKGROUND: Because patients may be taking clonidine chronically or may be receiving it as a premedication before surgery, the authors investigated its effect on cerebral hemodynamics. METHODS: In nine volunteers, middle cerebral artery mean blood flow velocity (Vm) was measured using transcranial Doppler ultrasonography (TCD). CO2 vasoreactivity was measured before clonidine administration (preclonidine), 90 min after clonidine, 5 microg/kg orally, then following restoration of mean arterial pressure (MAP) to the preclonidine level. In addition, Vm was measured after a phenylephrine-induced 30-mmHg increase in MAP. RESULTS: After clonidine administration, Vm decreased from 62 +/- 9 to 48 +/- 8 cm/s (P < 0.01), and MAP decreased from 86 +/- 10 to 63 +/- 5 mmHg (P < 0.01; mean +/- SD). Clonidine decreased the CO2 vasoreactivity slope from 2.2 +/- 0.4 to 1.2 +/- 0.5 cm x s(-1) x mmHg(-1) (P < 0.05); restoring MAP to the preclonidine level increased the slope to 1.60 +/- 0.5 cm x s(-1) x mmHg(-1), still less than the preclonidine slope (P < 0.05). CO2 vasoreactivity expressed as a percentage change in Vm, decreased after clonidine, 3.5 +/- 0.8 versus 2.4 +/- 0.8 %/mmHg (P < 0.05); this difference disappeared after restoration of MAP, 3.1 +/- 1.2 %/mmHg. With a 30-mmHg increase in MAP, Vm increased by 13% before and after clonidine (P < 0.05). CONCLUSIONS: Clonidine, 5 microg/kg orally, decreases Vm and slightly attenuates cerebral CO2 vasoreactivity, therefore decreased cerebral blood flow and mildly attenuated CO2 vasoreactivity should be anticipated.
No takes yet. Share an insight, caveat, or question.
Caldwell et al. (1997) studied Healthy volunteers (n=9). Clonidine vs. Preclonidine (baseline) was evaluated on Middle cerebral artery mean blood flow velocity (Vm) (p=< 0.01). Oral clonidine (5 microg/kg) decreased middle cerebral artery mean blood flow velocity from 62 to 48 cm/s and attenuated cerebral CO2 vasoreactivity in human volunteers.
Synapse has enriched 10 related papers. Consider them for comparative context: